Skip to content
Brand AI

Evotec

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    Bayer discontinues development of eliapixant

    Bayer decided to discontinue clinical development of eliapixant, an investigational P2X3 receptor antagonist. Evotec said it regained rights to all P2X3 assets and would evaluate the data when available.

    Source